Archive
All News
Every briefing, headline, and filing we've published, newest first.
PipelineFierceBiotech ↗
Kyverna Therapeutics has unveiled the full results from its registrational trial of miv-cel in stiff person sy…
Pipeline
Roche’s Enspryng cut MOGAD relapse risk by 68%, a pivotal step toward the first FDA-approved therapy for the d…
PipelineBioPharma Dive ↗
A program that got caught up in HHS’ decision to abandon mRNA research was revived by a public-private c…
PipelineSTAT News ↗
Flu shot no longer mandated for U.S. troops, "healthy" snacks, and other news from Morning Rounds…
PipelineFierceBiotech ↗
After dropping headline-grabbing phase 3 data for its pancreatic cancer candidate daraxonrasib, last Monday, R…
PipelineFiercePharma ↗
After prevailing in two kidney cancer trials in the refractory and early-stage settings, Merck & Co.’s blo…
DealsBriefing
UCB’s $650 million deal for Neurona Therapeutics signals a move to blend neurology heritage with next‑gen cell…
The WeekPharmaceutical Technology ↗
BioAegis Therapeutics has entered a strategic partnership with Prenosis to advance AI-driven precision medicin…
PolicySTAT News ↗
Health insurers would have likely faced a financial strain by participating in the Medicare pilot.…
PipelineEndpoints News ↗
A new HIV treatment will soon come to market, and it will spearhead Merck’s attempt to be one of the leading d…
PolicyKFF Health News ↗
Section 1115 Medicaid waivers can allow states to test new approaches in Medicaid that differ from what is req…
DataDrug Channels ↗
By Adam J. Fein, Ph.D.Drug Channels Institute’s (DCI’s) latest analysis reveals that PBM-affiliated specialty …
DealsFierceBiotech ↗
Eli Lilly is picking up its second in vivo CAR-T company of the year, paying $3.25 billion in upfront cash for…
PolicyFiercePharma ↗
President Donald Trump has ordered the FDA to perform priority reviews of psychedelic drugs as part of a push …
PolicyBriefing
HHS Secretary Robert F. Kennedy Jr. defended a proposed $16B budget cut, including $5B from NIH, as Republican…
DealsPharmaceutical Technology ↗
Asahi Kasei has completed its acquisition of Aicuris Anti-infective Cures, a German biopharmaceutical company.…
PipelineSTAT News ↗
At AACR, a bold use of CAR-T raises hopes and provocative questions about its use in smoldering multiple myelo…
PolicyEndpoints News ↗
Over the weekend, President Donald Trump endorsed the potential of psychedelic treatments and vowed to expedit…
DealsEndpoints News ↗
LONDON – Boehringer Ingelheim is growing its artificial intelligence arm to the UK by building a new hub in ce…
Deals
Lilly’s $3.25 billion upfront acquisition of Kelonia Therapeutics signals a bold move into in‑vivo CAR‑T techn…
PeoplePharmaVoice ↗
Where the rumored frontrunner stands on key issues like vaccines and public health policy.…
PolicyFierceBiotech ↗
President Donald Trump has ordered the FDA to perform priority reviews of psychedelic drugs as part of a push …
PipelineBriefing
Enflonsia, now cleared across the EU and EEA, promises single-dose, five-month protection against RSV, positio…
PipelineBioPharma Dive ↗
Learn how early coordination across functions, phases and partners can reduce risk and accelerate drug develop…
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.